Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

934
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
934
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data Volume and the Need for Clinical Decision Support in Glaucoma Care.

Ophthalmology science·2026
Same author

Machine Learning With Optical Coherence Tomography for Glaucoma Diagnosis.

Journal of glaucoma·2026
Same author

Association Between 24-Hour Blood Pressure and Rates of Retinal Nerve Fiber Layer Progression in Glaucoma: The Vascular Imaging in Glaucoma Study.

American journal of ophthalmology·2026
Same author

Incidence of Posterior Capsular Rupture in Routine and Complex Cataract Surgeries at a Major Training Institution.

Journal of cataract and refractive surgery·2026
Same author

Structure-Function Correlation of Virtual Reality and Standard Perimetry With Peripapillary RNFL OCT in Glaucoma Patients.

Translational vision science & technology·2026
Same author

Derivation and validation of clinical prediction models for viral etiologies of acute diarrhea in North American children presenting for emergency care.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jan 10, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.8K

Time to Identify Glaucoma Progression Given Typical Visual Field Testing Frequencies in a US Nationwide Insured

Brian C Stagg1, Ben J Brintz2, Joshua D Stein3

  • 1Department of Ophthalmology and Visual Sciences, John Moran Eye Center, University of Utah, Salt Lake City, Utah; Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.

Ophthalmology. Glaucoma
|November 28, 2025
PubMed
Summary

Glaucoma patients often have visual field tests less frequently than recommended. Simulation shows it can take over 24 years to detect progression at current testing rates, highlighting the need for more frequent screenings.

Keywords:
GlaucomaTesting frequencyVisual field

More Related Videos

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.8K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.5K

Related Experiment Videos

Last Updated: Jan 10, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.8K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.8K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.5K

Area of Science:

  • Ophthalmology
  • Medical Simulation
  • Public Health

Background:

  • Glaucoma visual field testing in the US occurs less frequently than the American Academy of Ophthalmology (AAO) recommended annual screening.
  • Median time between tests is 1.59 years, with an interquartile range of 1.14-3.03 years.

Purpose of the Study:

  • To determine the time required to detect glaucoma visual field progression based on current testing frequencies.
  • To compare detection times with AAO-recommended annual screening using simulation modeling.

Main Methods:

  • Retrospective clinical data from the Duke Glaucoma Registry (DGR) was used for simulation modeling.
  • Models evaluated progression detection times at various testing frequencies (25th, 50th, 75th percentiles, and annual).
  • Simulations incorporated different baseline mean deviations (MD) and rates of progression, defining progression as a significant negative MD slope.

Main Results:

  • Time to detect 80% of progression ranged from 7.1 to 24.3 years across testing scenarios.
  • Less frequent testing (e.g., every 3.03 years) extended detection time to over 24 years.
  • Annual testing reduced detection time, ranging from 7.1 to 14.1 years.

Conclusions:

  • Current visual field testing frequency is insufficient for timely glaucoma progression detection.
  • More frequent testing or development of alternative detection methods is necessary.
  • Clinical decision support systems could personalize visual field testing frequency.